Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBIT Margin (2017 - 2025)

Neurocrine Biosciences' EBIT Margin history spans 15 years, with the latest figure at 26.18% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 356.0% year-over-year to 26.18%; the TTM value through Dec 2025 reached 21.64%, down 258.0%, while the annual FY2025 figure was 21.64%, 258.0% down from the prior year.
  • EBIT Margin reached 26.18% in Q4 2025 per NBIX's latest filing, down from 30.07% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 550.0% in Q4 2021 to a low of 27.16% in Q1 2023.
  • Average EBIT Margin over 5 years is 57.33%, with a median of 22.63% recorded in 2022.
  • Peak YoY movement for EBIT Margin: surged 52104bps in 2021, then crashed -52490bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 550.0% in 2021, then plummeted by -95bps to 25.1% in 2022, then increased by 16bps to 29.17% in 2023, then dropped by -22bps to 22.62% in 2024, then increased by 16bps to 26.18% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBIT Margin are 26.18% (Q4 2025), 30.07% (Q3 2025), and 21.18% (Q2 2025).